Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.

Labidi-Galy SI, de La Motte Rouge T, Derbel O, Wolfer A, Kalbacher E, Olivier T, Combes JD, Heimgartner-Hu K, Tredan O, Guevara H, Heudel PE, Reverdy T, Bazan F, Heinzelmann-Schwarz V, Fehr M, de Castelbajac V, Vaflard P, Crivelli L, Bonadona V, Viassolo V, Buisson A, Golmard L, Rodrigues M, Ray-Coquard I.

Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31528-8. doi: 10.1016/j.ygyno.2019.09.008. [Epub ahead of print]

PMID:
31604666
2.

Outcome in serous ovarian cancer is not associated with LATS expression.

Montavon C, Stricker GR, Schoetzau A, Heinzelmann-Schwarz V, Jacob F, Fedier A.

J Cancer Res Clin Oncol. 2019 Oct 4. doi: 10.1007/s00432-019-03037-4. [Epub ahead of print]

PMID:
31586262
3.

A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer.

Hüttenhain R, Choi M, Martin de la Fuente L, Oehl K, Chang CV, Zimmermann AK, Malander S, Olsson H, Surinova S, Clough T, Heinzelmann-Schwarz V, Wild PJ, Dinulescu DM, Niméus E, Vitek O, Aebersold R.

Mol Cell Proteomics. 2019 Sep;18(9):1836-1850. doi: 10.1074/mcp.RA118.001221. Epub 2019 Jul 9.

PMID:
31289117
4.

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.

Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, Albrecht R, Herter S, Schlenker R, Hüsser T, Diggelmann S, Challier J, Mössner E, Hosse RJ, Hofer T, Brünker P, Joseph C, Benz J, Ringler P, Stahlberg H, Lauer M, Perro M, Chen S, Küttel C, Bhavani Mohan PL, Nicolini V, Birk MC, Ongaro A, Prince C, Gianotti R, Dugan G, Whitlow CT, Solingapuram Sai KK, Caudell DL, Burgos-Rodriguez AG, Cline JM, Hettich M, Ceppi M, Giusti AM, Crameri F, Driessen W, Morcos PN, Freimoser-Grundschober A, Levitsky V, Amann M, Grau-Richards S, von Hirschheydt T, Tournaviti S, Mølhøj M, Fauti T, Heinzelmann-Schwarz V, Teichgräber V, Colombetti S, Bacac M, Zippelius A, Klein C, Umaña P.

Sci Transl Med. 2019 Jun 12;11(496). pii: eaav5989. doi: 10.1126/scitranslmed.aav5989.

PMID:
31189721
5.

Fibrin-thrombin sealant does not reduce lymphocele formation in patients with inguinofemoral lymphadenectomy for vulvar cancer.

Saner FA, Schötzau A, Mackay G, Heinzelmann-Schwarz V, Montavon Sartorius C.

Cancer Manag Res. 2019 Apr 30;11:3575-3582. doi: 10.2147/CMAR.S197143. eCollection 2019.

6.

A forgotten disease: Pelvic congestion syndrome as a cause of chronic lower abdominal pain.

Jurga-Karwacka A, Karwacki GM, Schoetzau A, Zech CJ, Heinzelmann-Schwarz V, Schwab FD.

PLoS One. 2019 Apr 2;14(4):e0213834. doi: 10.1371/journal.pone.0213834. eCollection 2019.

7.

Neutrophils escort circulating tumour cells to enable cell cycle progression.

Szczerba BM, Castro-Giner F, Vetter M, Krol I, Gkountela S, Landin J, Scheidmann MC, Donato C, Scherrer R, Singer J, Beisel C, Kurzeder C, Heinzelmann-Schwarz V, Rochlitz C, Weber WP, Beerenwinkel N, Aceto N.

Nature. 2019 Feb;566(7745):553-557. doi: 10.1038/s41586-019-0915-y. Epub 2019 Feb 6.

PMID:
30728496
8.

Challenges and Opportunities for Cancer Predisposition Cascade Screening for Hereditary Breast and Ovarian Cancer and Lynch Syndrome in Switzerland: Findings from an International Workshop.

Nikolaidis C, Ming C, Pedrazzani C, van der Horst T, Kaiser-Grolimund A, Ademi Z, Bührer-Landolt R, Bürki N, Caiata-Zufferey M, Champion V, Chappuis PO, Kohler C, Erlanger TE, Graffeo R, Hampel H, Heinimann K, Heinzelmann-Schwarz V, Kurzeder C, Monnerat C, Northouse LL, Pagani O, Probst-Hensch N, Rabaglio M, Schoenau E, Sijbrands EJG, Taborelli M, Urech C, Viassolo V, Wieser S, Katapodi MC; for the CASCADE Consortium.

Public Health Genomics. 2018;21(3-4):121-132. doi: 10.1159/000496495. Epub 2019 Jan 29.

PMID:
30695780
9.

Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding.

Gkountela S, Castro-Giner F, Szczerba BM, Vetter M, Landin J, Scherrer R, Krol I, Scheidmann MC, Beisel C, Stirnimann CU, Kurzeder C, Heinzelmann-Schwarz V, Rochlitz C, Weber WP, Aceto N.

Cell. 2019 Jan 10;176(1-2):98-112.e14. doi: 10.1016/j.cell.2018.11.046.

10.

Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer.

Vetter M, Landin J, Szczerba BM, Castro-Giner F, Gkountela S, Donato C, Krol I, Scherrer R, Balmelli C, Malinovska A, Zippelius A, Kurzeder C, Heinzelmann-Schwarz V, Weber WP, Rochlitz C, Aceto N.

Breast Cancer Res. 2018 Nov 20;20(1):141. doi: 10.1186/s13058-018-1067-y.

11.

Impact of the new FIGO 2013 classification on prognosis of stage I epithelial ovarian cancers.

Montavon Sartorius C, Mirza U, Schötzau A, Mackay G, Fink D, Hacker NF, Heinzelmann-Schwarz V.

Cancer Manag Res. 2018 Oct 17;10:4709-4718. doi: 10.2147/CMAR.S174777. eCollection 2018.

12.

Ovarian cancer in Switzerland: incidence and treatment according to hospital registry data.

Wieser S, Schmidt M, Kind AB, Heinzelmann-Schwarz VA.

Swiss Med Wkly. 2018 Jul 29;148:w14647. doi: smw.2018.14647. eCollection 2018 Jul 16.

13.

Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.

Stanczak MA, Siddiqui SS, Trefny MP, Thommen DS, Boligan KF, von Gunten S, Tzankov A, Tietze L, Lardinois D, Heinzelmann-Schwarz V, von Bergwelt-Baildon M, Zhang W, Lenz HJ, Han Y, Amos CI, Syedbasha M, Egli A, Stenner F, Speiser DE, Varki A, Zippelius A, Läubli H.

J Clin Invest. 2018 Nov 1;128(11):4912-4923. doi: 10.1172/JCI120612. Epub 2018 Sep 24.

14.

Diaphragmatic smears are not of additional benefit in the detection of peritoneal spread in gynecological cancers.

Montavon C, Mirza U, Fedier A, Schoetzau A, Zanetti Dällenbach R, Heinzelmann-Schwarz V.

Exp Ther Med. 2018 May;15(5):4199-4204. doi: 10.3892/etm.2018.5957. Epub 2018 Mar 13.

15.

ABO blood groups as a prognostic factor for recurrence in ovarian and vulvar cancer.

Montavon Sartorius C, Schoetzau A, Kettelhack H, Fink D, Hacker NF, Fedier A, Jacob F, Heinzelmann-Schwarz V.

PLoS One. 2018 Mar 29;13(3):e0195213. doi: 10.1371/journal.pone.0195213. eCollection 2018.

16.

Transition of Mesenchymal and Epithelial Cancer Cells Depends on α1-4 Galactosyltransferase-Mediated Glycosphingolipids.

Jacob F, Alam S, Konantz M, Liang CY, Kohler RS, Everest-Dass AV, Huang YL, Rimmer N, Fedier A, Schötzau A, Lopez MN, Packer NH, Lengerke C, Heinzelmann-Schwarz V.

Cancer Res. 2018 Jun 1;78(11):2952-2965. doi: 10.1158/0008-5472.CAN-17-2223. Epub 2018 Mar 23.

17.

Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients.

Heinzelmann-Schwarz V, Knipprath Mészaros A, Stadlmann S, Jacob F, Schoetzau A, Russell K, Friedlander M, Singer G, Vetter M.

Gynecol Oncol. 2018 Jan;148(1):79-85. doi: 10.1016/j.ygyno.2017.10.036. Epub 2017 Nov 20.

18.

Spontaneous Remission of Severe Systemic Langerhans Cell Histiocytosis with Bladder Involvement: A Case Study.

Magaton IM, Tzankov A, Krasniqi F, Rottenburger C, Zanetti-Daellenbach R, Grendelmeier P, Heinzelmann-Schwarz V, Mayr M, Schwab FD.

Case Rep Oncol. 2017 Oct 5;10(3):876-884. doi: 10.1159/000480696. eCollection 2017 Sep-Dec.

19.

Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol.

Katapodi MC, Viassolo V, Caiata-Zufferey M, Nikolaidis C, Bührer-Landolt R, Buerki N, Graffeo R, Horváth HC, Kurzeder C, Rabaglio M, Scharfe M, Urech C, Erlanger TE, Probst-Hensch N, Heinimann K, Heinzelmann-Schwarz V, Pagani O, Chappuis PO.

JMIR Res Protoc. 2017 Sep 20;6(9):e184. doi: 10.2196/resprot.8138.

20.

Tissue glycomics distinguish tumour sites in women with advanced serous adenocarcinoma.

Anugraham M, Jacob F, Everest-Dass AV, Schoetzau A, Nixdorf S, Hacker NF, Fink D, Heinzelmann-Schwarz V, Packer NH.

Mol Oncol. 2017 Nov;11(11):1595-1615. doi: 10.1002/1878-0261.12134. Epub 2017 Sep 29.

21.

MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells.

Kohler RS, Kettelhack H, Knipprath-Mészaros AM, Fedier A, Schoetzau A, Jacob F, Heinzelmann-Schwarz V.

Gynecol Oncol. 2017 Apr;145(1):159-166. doi: 10.1016/j.ygyno.2017.02.016. Epub 2017 Feb 14.

22.

Naturally occurring anti-glycan antibodies binding to Globo H-expressing cells identify ovarian cancer patients.

Pochechueva T, Alam S, Schötzau A, Chinarev A, Bovin NV, Hacker NF, Jacob F, Heinzelmann-Schwarz V.

J Ovarian Res. 2017 Feb 10;10(1):8. doi: 10.1186/s13048-017-0305-8.

23.

Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients.

Pochechueva T, Chinarev A, Schoetzau A, Fedier A, Bovin NV, Hacker NF, Jacob F, Heinzelmann-Schwarz V.

PLoS One. 2016 Oct 20;11(10):e0164230. doi: 10.1371/journal.pone.0164230. eCollection 2016.

24.

Long-term quality of life, satisfaction, pelvic floor symptoms and regret after colpocleisis.

Katsara A, Wight E, Heinzelmann-Schwarz V, Kavvadias T.

Arch Gynecol Obstet. 2016 Nov;294(5):999-1003. Epub 2016 Jul 26.

PMID:
27460073
25.

Epigenetic activation of MGAT3 and corresponding bisecting GlcNAc shortens the survival of cancer patients.

Kohler RS, Anugraham M, López MN, Xiao C, Schoetzau A, Hettich T, Schlotterbeck G, Fedier A, Jacob F, Heinzelmann-Schwarz V.

Oncotarget. 2016 Aug 9;7(32):51674-51686. doi: 10.18632/oncotarget.10543.

26.

Improved Detection Rate of Ovarian Cancer Using a 2-Step Triage Model of the Risk of Malignancy Index and Expert Sonography in an Outpatient Screening Setting.

Manegold-Brauer G, Buechel J, Knipprath-Mészaros A, Schoetzau A, Hacker NF, Tercanli S, Lapaire O, Heinzelmann-Schwarz V.

Int J Gynecol Cancer. 2016 Jul;26(6):1062-9. doi: 10.1097/IGC.0000000000000718.

PMID:
27177281
27.

Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor.

Schreiner J, Thommen DS, Herzig P, Bacac M, Klein C, Roller A, Belousov A, Levitsky V, Savic S, Moersig W, Uhlenbrock F, Heinzelmann-Schwarz VA, Umana P, Pisa P, von Bergwelt-Baildon M, Lardinois D, Müller P, Karanikas V, Zippelius A.

Oncoimmunology. 2015 Jun 24;5(2):e1062969. eCollection 2016 Feb.

28.

Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion.

Henry C, Llamosas E, Knipprath-Meszaros A, Schoetzau A, Obermann E, Fuenfschilling M, Caduff R, Fink D, Hacker N, Ward R, Heinzelmann-Schwarz V, Ford C.

Oncotarget. 2015 Nov 24;6(37):40310-26. doi: 10.18632/oncotarget.5643.

29.

Alterations in the mitochondrial responses to PENAO as a mechanism of resistance in ovarian cancer cells.

Decollogne S, Joshi S, Chung SA, Luk PP, Yeo RX, Nixdorf S, Fedier A, Heinzelmann-Schwarz V, Hogg PJ, Dilda PJ.

Gynecol Oncol. 2015 Aug;138(2):363-71. doi: 10.1016/j.ygyno.2015.06.018. Epub 2015 Jun 14.

PMID:
26080289
30.

Comment on the letter: the mass cannot be classified as malignant.

Manegold-Brauer G, Heinzelmann-Schwarz V.

Arch Gynecol Obstet. 2015 Mar;291(3):475. doi: 10.1007/s00404-014-3558-0. No abstract available.

PMID:
25488156
31.

Expression of GBGT1 is epigenetically regulated by DNA methylation in ovarian cancer cells.

Jacob F, Hitchins MP, Fedier A, Brennan K, Nixdorf S, Hacker NF, Ward R, Heinzelmann-Schwarz VA.

BMC Mol Biol. 2014 Oct 7;15:24. doi: 10.1186/1471-2199-15-24.

32.

The glycosphingolipid P₁ is an ovarian cancer-associated carbohydrate antigen involved in migration.

Jacob F, Anugraham M, Pochechueva T, Tse BW, Alam S, Guertler R, Bovin NV, Fedier A, Hacker NF, Huflejt ME, Packer N, Heinzelmann-Schwarz VA.

Br J Cancer. 2014 Oct 14;111(8):1634-45. doi: 10.1038/bjc.2014.455. Epub 2014 Aug 28.

33.

PEGylation of microbead surfaces reduces unspecific antibody binding in glycan-based suspension array.

Pochechueva T, Chinarev A, Bovin N, Fedier A, Jacob F, Heinzelmann-Schwarz V.

J Immunol Methods. 2014 Oct;412:42-52. doi: 10.1016/j.jim.2014.06.015. Epub 2014 Jul 1.

34.

Reliable in vitro studies require appropriate ovarian cancer cell lines.

Jacob F, Nixdorf S, Hacker NF, Heinzelmann-Schwarz VA.

J Ovarian Res. 2014 Jun 7;7:60. doi: 10.1186/1757-2215-7-60. eCollection 2014. Review.

35.

The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer.

Ford CE, Punnia-Moorthy G, Henry CE, Llamosas E, Nixdorf S, Olivier J, Caduff R, Ward RL, Heinzelmann-Schwarz V.

Gynecol Oncol. 2014 Aug;134(2):338-45. doi: 10.1016/j.ygyno.2014.06.004. Epub 2014 Jun 10.

PMID:
24924122
36.

Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells.

Müller P, Martin K, Theurich S, Schreiner J, Savic S, Terszowski G, Lardinois D, Heinzelmann-Schwarz VA, Schlaak M, Kvasnicka HM, Spagnoli G, Dirnhofer S, Speiser DE, von Bergwelt-Baildon M, Zippelius A.

Cancer Immunol Res. 2014 Aug;2(8):741-55. doi: 10.1158/2326-6066.CIR-13-0198. Epub 2014 Apr 21.

37.

The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity.

Martin K, Müller P, Schreiner J, Prince SS, Lardinois D, Heinzelmann-Schwarz VA, Thommen DS, Zippelius A.

Cancer Immunol Immunother. 2014 Sep;63(9):925-38. doi: 10.1007/s00262-014-1565-4. Epub 2014 Jun 7.

PMID:
24906866
38.

Specific glycosylation of membrane proteins in epithelial ovarian cancer cell lines: glycan structures reflect gene expression and DNA methylation status.

Anugraham M, Jacob F, Nixdorf S, Everest-Dass AV, Heinzelmann-Schwarz V, Packer NH.

Mol Cell Proteomics. 2014 Sep;13(9):2213-32. doi: 10.1074/mcp.M113.037085. Epub 2014 May 22.

39.

Management of human papillomavirus-related gynecological malignancies.

Heinzelmann-Schwarz VA, Kind AB, Jacob F.

Curr Probl Dermatol. 2014;45:216-24. doi: 10.1159/000358408. Epub 2014 Mar 13.

PMID:
24643189
40.

A clinicopathological review of 33 patients with vulvar melanoma identifies c-KIT as a prognostic marker.

Heinzelmann-Schwarz VA, Nixdorf S, Valadan M, Diczbalis M, Olivier J, Otton G, Fedier A, Hacker NF, Scurry JP.

Int J Mol Med. 2014 Apr;33(4):784-94. doi: 10.3892/ijmm.2014.1659. Epub 2014 Feb 14. Review.

41.

Antibody-based immunotherapy for ovarian cancer: where are we at?

Tse BW, Collins A, Oehler MK, Zippelius A, Heinzelmann-Schwarz VA.

Ann Oncol. 2014 Feb;25(2):322-31. doi: 10.1093/annonc/mdt405. Epub 2013 Nov 26. Review.

PMID:
24285017
42.

The special role of ultrasound for screening, staging and surveillance of malignant ovarian tumors: distinction from other methods of diagnostic imaging.

Manegold-Brauer G, Bellin AK, Tercanli S, Lapaire O, Heinzelmann-Schwarz V.

Arch Gynecol Obstet. 2014 Mar;289(3):491-8. doi: 10.1007/s00404-013-3081-8. Epub 2013 Nov 20. Review.

PMID:
24253338
43.

Impact of breast cancer family history on tumor detection and tumor size in women newly-diagnosed with invasive breast cancer.

Schwab FD, Bürki N, Huang DJ, Heinzelmann-Schwarz V, Schmid SM, Vetter M, Schötzau A, Güth U.

Fam Cancer. 2014 Mar;13(1):99-107. doi: 10.1007/s10689-013-9682-3.

PMID:
24002368
44.

Meta-analysis of microarray data identifies GAS6 expression as an independent predictor of poor survival in ovarian cancer.

Buehler M, Tse B, Leboucq A, Jacob F, Caduff R, Fink D, Goldstein DR, Heinzelmann-Schwarz V.

Biomed Res Int. 2013;2013:238284. doi: 10.1155/2013/238284. Epub 2013 Jun 27.

45.

Careful selection of reference genes is required for reliable performance of RT-qPCR in human normal and cancer cell lines.

Jacob F, Guertler R, Naim S, Nixdorf S, Fedier A, Hacker NF, Heinzelmann-Schwarz V.

PLoS One. 2013;8(3):e59180. doi: 10.1371/journal.pone.0059180. Epub 2013 Mar 15. Review.

46.

Staging for distant metastases in operable breast cancer: a suggested expansion of the ESMO guideline recommendation for staging imaging of node-negative, hormonal receptor-negative disease.

Güth U, Vetter M, Huang DJ, Heinzelmann-Schwarz V.

Ann Oncol. 2013 Feb;24(2):555-7. doi: 10.1093/annonc/mds637. No abstract available.

PMID:
23341481
47.

The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells.

Ford CE, Jary E, Ma SS, Nixdorf S, Heinzelmann-Schwarz VA, Ward RL.

PLoS One. 2013;8(1):e54362. doi: 10.1371/journal.pone.0054362. Epub 2013 Jan 11.

48.

LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.

Cowin PA, George J, Fereday S, Loehrer E, Van Loo P, Cullinane C, Etemadmoghadam D, Ftouni S, Galletta L, Anglesio MS, Hendley J, Bowes L, Sheppard KE, Christie EL, Pearson RB, Harnett PR, Heinzelmann-Schwarz V, Friedlander M, McNally O, Quinn M, Campbell P, deFazio A, Bowtell DD; Australian Ovarian Cancer Study.

Cancer Res. 2012 Aug 15;72(16):4060-73.

49.

Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients.

Jacob F, Ukegjini K, Nixdorf S, Ford CE, Olivier J, Caduff R, Scurry JP, Guertler R, Hornung D, Mueller R, Fink DA, Hacker NF, Heinzelmann-Schwarz VA.

PLoS One. 2012;7(2):e31885. doi: 10.1371/journal.pone.0031885. Epub 2012 Feb 21.

50.

Tumor-associated glycans and their role in gynecological cancers: accelerating translational research by novel high-throughput approaches.

Pochechueva T, Jacob F, Fedier A, Heinzelmann-Schwarz V.

Metabolites. 2012 Nov 14;2(4):913-39. doi: 10.3390/metabo2040913.

Supplemental Content

Loading ...
Support Center